Maddalena Barba

Summary

Affiliation: Regina Elena Cancer Institute
Country: Italy

Publications

  1. ncbi Perinatal exposures and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study
    Maddalena Barba
    Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA
    Cancer Causes Control 17:395-401. 2006
  2. doi Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, Buffalo, New York 14215, USA
    Cancer 113:1685-94. 2008
  3. ncbi Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 4:CD006652. 2011
  4. pmc Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, Buffalo, NY, USA
    J Exp Clin Cancer Res 27:21. 2008
  5. ncbi Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 11:CD009447. 2011
  6. ncbi Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 1:CD006652. 2011
  7. ncbi Extended perioperative thromboprophylaxis in patients with cancer. A systematic review
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider St, Buffalo, NY 14215, USA
    Thromb Haemost 100:1176-80. 2008
  8. pmc Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, NY, USA
    J Exp Clin Cancer Res 27:4. 2008
  9. ncbi Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, Erie County Medical Center CC 142, 462 Grider St, Buffalo, NY 14215, USA
    Arch Intern Med 168:1261-9. 2008
  10. ncbi Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 6:CD006466. 2011

Collaborators

Detail Information

Publications24

  1. ncbi Perinatal exposures and breast cancer risk in the Western New York Exposures and Breast Cancer (WEB) Study
    Maddalena Barba
    Department of Social and Preventive Medicine, School of Public Health and Health Professions, University at Buffalo, Buffalo, NY, USA
    Cancer Causes Control 17:395-401. 2006
    ..There is increasing evidence that early life exposures, such as birth weight, infant feeding practices, birth rank and maternal age at delivery may play a role in breast carcinogenesis...
  2. doi Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, Buffalo, New York 14215, USA
    Cancer 113:1685-94. 2008
    ..The authors compared the relative efficacy and safety of low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) for the initial treatment of venous thromboembolism (VTE) between patients with and without cancer...
  3. ncbi Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 4:CD006652. 2011
    ..Anticoagulation may improve survival in patients with cancer through an antitumor effect in addition to the perceived antithrombotic effect...
  4. pmc Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, Buffalo, NY, USA
    J Exp Clin Cancer Res 27:21. 2008
    ..The objective of this study was to compare low molecular weight heparin (LMWH) and oral anticoagulants (vitamin K antagonist (VKA) and ximelagatran) for the long term treatment of venous thromboembolism in patients with cancer...
  5. ncbi Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 11:CD009447. 2011
    ..The choice of the appropriate perioperative thromboprophylaxis in patients with cancer depends on the relative benefits and harms of low molecular weight heparin (LMWH) and unfractionated heparin (UFH)...
  6. ncbi Parenteral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 1:CD006652. 2011
    ..Anticoagulation may improve survival in patients with cancer through an antitumor effect in addition to the perceived antithrombotic effect...
  7. ncbi Extended perioperative thromboprophylaxis in patients with cancer. A systematic review
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider St, Buffalo, NY 14215, USA
    Thromb Haemost 100:1176-80. 2008
    ..More and better quality evidence is needed to justify extended regimens...
  8. pmc Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, NY, USA
    J Exp Clin Cancer Res 27:4. 2008
    ..To determine the efficacy and safety of heparin (unfractionated heparin (UFH) or low-molecular-weight-heparin (LMWH)) and fondaparinux in improving the survival of patients with cancer...
  9. ncbi Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, Erie County Medical Center CC 142, 462 Grider St, Buffalo, NY 14215, USA
    Arch Intern Med 168:1261-9. 2008
    ..We systematically reviewed the literature to quantify these effects...
  10. ncbi Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 6:CD006466. 2011
    ..A number of basic research and clinical studies have led to the hypothesis that oral anticoagulants may improve the survival of patients with cancer through an antitumor effect in addition to their antithrombotic effect...
  11. ncbi Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 6:CD006649. 2011
    ..Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)...
  12. ncbi Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 4:CD006649. 2011
    ..Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)...
  13. ncbi Anticoagulation for patients with cancer and central venous catheters
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 4:CD006468. 2011
    ..Central venous catheter (CVC) placement increases the risk of thrombosis in cancer patients. Thrombosis often necessitates the removal of the CVC, resulting in treatment delays and thrombosis related morbidity and mortality...
  14. ncbi Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 2:CD006649. 2011
    ..Compared to patients without cancer, patients with cancer who receive anticoagulant treatment for venous thromboembolism are more likely to develop recurrent venous thromboembolism (VTE)...
  15. ncbi Anticoagulation for patients with cancer and central venous catheters
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 2:CD006468. 2011
    ..Central venous catheter (CVC) placement increases the risk of thrombosis in cancer patients. Thrombosis often necessitates the removal of the CVC, resulting in treatment delays and thrombosis related morbidity and mortality...
  16. ncbi Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 6:CD006650. 2011
    ..Cancer increases the risk of thromboembolic events even while on anticoagulation...
  17. ncbi Erythrocyte membrane phospholipid composition as a biomarker of dietary fat
    Barbara J Fuhrman
    Department of Social and Preventive Medicine, University at Buffalo, State University of New York, Buffalo, NY 14214, USA
    Ann Nutr Metab 50:95-102. 2006
    ....
  18. pmc An instrument to assess quality of life in relation to nutrition: item generation, item reduction and initial validation
    Holger J Schunemann
    Department of Medicine, University at Buffalo, State University of New York, Buffalo, New York, USA
    Health Qual Life Outcomes 8:26. 2010
    ..Therefore, the aim of this project was to develop an instrument for measuring QoL related to nutrition in the general population...
  19. ncbi Serum fructosamine and subsequent breast cancer risk: a nested case-control study in the ORDET prospective cohort study
    Mary Platek
    Department of Exercise and Nutrition Sciences, University at Buffalo, State University of New York, 270 Farber Hall, 3435 Main Street, 14214 Buffalo, NY, USA
    Cancer Epidemiol Biomarkers Prev 14:271-4. 2005
    ..58 (95% CI, 0.76-3.40) and in postmenopausal women, the OR was 1.60 (95% CI, 0.76-3.48). Serum fructosamine levels tended to be positively associated with breast cancer risk independent of menopausal status...
  20. ncbi Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, ECMC CC 142, 462 Grider Street, Buffalo, NY, USA, 14215
    Cochrane Database Syst Rev 12:CD006466. 2010
    ..A number of basic research and clinical studies have led to the hypothesis that oral anticoagulants may improve the survival of patients with cancer through an antitumor effect in addition to their antithrombotic effect...
  21. ncbi Basal growth hormone concentrations in blood and the risk for prostate cancer: a case-control study
    Barbara Fuhrman
    Department of Social and Preventive Medicine, University at Buffalo, State University of New York, Buffalo, NY 14214, USA
    Prostate 64:109-15. 2005
    ..To assess the relationship between basal serum growth hormone (GH) levels and prostate cancer risk...
  22. doi Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis
    Elie A Akl
    Department of Medicine, State University of New York at Buffalo, Buffalo, NY 14215, USA
    Cancer 112:2483-92. 2008
    ..The objective of this systematic review was to determine the efficacy and safety of anticoagulation in reducing mortality and thromboembolic events in cancer patients with a CVC...
  23. doi Indicators of sexual and somatic development and adolescent body size in relation to prostate cancer risk: results from a case-control study
    Maddalena Barba
    Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy
    Urology 72:183-7. 2008
    ....
  24. doi Equol status modifies the association of soy intake and mammographic density in a sample of postmenopausal women
    Barbara J Fuhrman
    Department of Epidemiology, Italian National Cancer Institute Regina Elena, Via Elio Chianesi 53, Rome, Italy
    Cancer Epidemiol Biomarkers Prev 17:33-42. 2008
    ..5% in weekly soy consumers versus 30.7% in others; P = 0.03). Results suggest that equol producers and nonproducers may experience different effects of dietary soy on breast tissue...